Morgan Stanley
FTH

Morgan Stanley’s Faeth Therapeutics FTH Stock Holding History

Morgan Stanley’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433K Buy
17,329
+8,534
+97% +$197K ﹤0.01% 5614
2026
Q1 		$277K Buy
8,795
+8,785
+87,850% +$176K ﹤0.01% 5728
2025
Q4 		$107 Hold
10
– – ﹤0.01% 7704
2025
Q3 		$95 Hold
10
– – ﹤0.01% 7694
2025
Q2 		$86 Sell
10
-451
-98% -$3.24K ﹤0.01% 7672
2025
Q1 		$3.63K Hold
461
– – ﹤0.01% 7069
2024
Q4 		$4.52K Sell
461
-150
-25% -$1.5K ﹤0.01% 7029
2024
Q3 		$7.31K Hold
611
– – ﹤0.01% 6806
2024
Q2 		$7.58K Hold
611
– – ﹤0.01% 6754
2024
Q1 		$12.8K Buy
611
+600
+5,455% +$10.3K ﹤0.01% 6608
2023
Q4 		$151 Hold
11
– – ﹤0.01% 7320
2023
Q3 		$175 Hold
11
– – ﹤0.01% 7397
2023
Q2 		$250 Sell
11
-6,421
-100% -$188K ﹤0.01% 7436
2023
Q1 		$193K Buy
6,432
+6,420
+53,500% +$190K ﹤0.01% 5722
2022
Q4 		$371 Sell
12
-666
-98% -$19.6K ﹤0.01% 7591
2022
Q3 		$21K Sell
678
-631
-48% -$24.8K ﹤0.01% 6773
2022
Q2 		$59K Buy
1,309
+755
+136% +$28.3K ﹤0.01% 6542
2022
Q1 		$25K Sell
554
-1,288
-70% -$102K ﹤0.01% 7048
2021
Q4 		$214K Buy
1,842
+1,676
+1,010% +$250K ﹤0.01% 6025
2021
Q3 		$35K Sell
166
-5,220
-97% -$950K ﹤0.01% 6873
2021
Q2 		$1.05M Buy
5,386
+5,057
+1,537% +$1.25M ﹤0.01% 5042
2021
Q1 		$96K Buy
+329
New +$110K ﹤0.01% 6042

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Morgan Stanley's FTH Position: Q2 2026 in Review

Morgan Stanley increased its Faeth Therapeutics (FTH) stake by 97% in Q2 2026, buying an estimated $197K and bringing the position to 17,329 shares worth $433K. The position accounts for ﹤0.01% of the portfolio, ranked #5614.

Morgan Stanley first reported a position in FTH in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.05M in Q2 2021. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Morgan Stanley held 17,329 shares of Faeth Therapeutics worth $433K as of Q2 2026.
  • Morgan Stanley bought 8,534 Faeth Therapeutics shares in Q2 2026, an estimated $197K.
  • Faeth Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5614 holding.
  • Morgan Stanley first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Morgan Stanley's Faeth Therapeutics position peaked at $1.05M in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.